US Stock MarketDetailed Quotes
GLUE Monte Rosa Therapeutics
- 5.330
- -0.120-2.20%
Close Apr 26 16:00 ET
- 5.250
- -0.080-1.50%
Post 18:37 ET
268.23MMarket Cap-2026P/E (TTM)
5.500High5.290Low87.74KVolume5.369Open5.450Pre Close473.21KTurnover0.37%Turnover RatioLossP/E (Static)50.33MShares8.84052wk High1.50P/B127.03MFloat Cap2.44052wk Low--Dividend TTM23.83MShs Float45.560Historical High--Div YieldTTM3.85%Amplitude2.440Historical Low5.393Avg Price1Lot Size
Monte Rosa Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 52.63%-43.8M | 223.68%29.63M | -19.93%-24.71M | -23.53%-25.32M | 14.59%-23.41M | -55.76%-92.47M | -69.07%-23.96M | -15.77%-20.6M | -50.94%-20.5M | -98.36%-27.4M |
| Net income from continuing operations | -24.75%-135.35M | -8.02%-33.25M | -27.70%-34.88M | -32.90%-35.18M | -33.87%-32.04M | -46.71%-108.5M | -31.32%-30.78M | -37.71%-27.32M | -43.81%-26.47M | -94.95%-23.93M |
| Operating gains losses | 198.17%107K | --0 | --0 | ---24K | 204.80%131K | -741.18%-109K | --0 | --16K | --0 | ---125K |
| Depreciation and amortization | 66.14%6.22M | 72.52%1.85M | 77.54%1.83M | 56.47%1.39M | 52.86%1.15M | 75.66%3.75M | 32.26%1.07M | 77.49%1.03M | 90.36%889K | 174.82%753K |
| Other non cash items | ---- | ---- | ---- | ---- | ---- | 401.46%4.81M | --1.61M | --1.54M | --1.28M | -60.52%379K |
| Change In working capital | 3,495.78%72.47M | 2,683.55%57.7M | 245.42%4.37M | 374.26%5.75M | 169.44%4.64M | -133.95%-2.13M | -68.59%2.07M | 302.56%1.27M | -63.68%1.21M | -120.99%-6.69M |
| -Change in receivables | 1,114.44%1.9M | -3,260.00%-336K | 311.86%375K | ---195K | --2.05M | ---187K | ---10K | ---177K | --0 | --0 |
| -Change in prepaid assets | 150.63%1.08M | 15,400.00%765K | 83.61%-235K | 2,433.75%1.87M | -117.11%-1.32M | -202.13%-2.13M | -100.56%-5K | 36.44%-1.43M | -103.91%-80K | 55.97%-608K |
| -Change in payables and accrued expense | 3,145.64%9.32M | 216.88%7.06M | 23.94%3.47M | 76.30%1.76M | 48.13%-2.98M | -95.12%287K | -51.60%2.23M | 71.86%2.8M | -22.66%1M | -249.33%-5.74M |
| -Change in other working capital | 56,340.19%60.18M | 36,227.34%50.22M | 925.68%759K | 692.12%2.31M | 2,162.28%6.89M | -109.65%-107K | ---139K | --74K | --292K | ---334K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 52.63%-43.8M | 223.68%29.63M | -19.93%-24.71M | -23.53%-25.32M | 14.59%-23.41M | -55.76%-92.47M | -69.07%-23.96M | -15.77%-20.6M | -50.94%-20.5M | -98.36%-27.4M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 140.51%88.8M | 126.51%14.3M | 20.82%35.63M | 230.18%18.55M | 111.26%20.33M | -2,170.99%-219.22M | -1,670.23%-53.94M | 1,846.98%29.49M | -427.55%-14.25M | -8,042.53%-180.52M |
| Net PPE purchase and sale | -48.25%-18.98M | 76.77%-1.69M | -17.16%-1.66M | -152.64%-6.45M | -487.77%-9.18M | -32.62%-12.8M | -138.63%-7.27M | 16.11%-1.42M | 5.48%-2.55M | 29.54%-1.56M |
| Net investment purchase and sale | 152.21%107.78M | 134.25%15.99M | 20.65%37.29M | 313.75%25M | 116.49%29.51M | ---206.42M | ---46.67M | --30.91M | ---11.7M | ---178.96M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 140.51%88.8M | 126.51%14.3M | 20.82%35.63M | 230.18%18.55M | 111.26%20.33M | -2,170.99%-219.22M | -1,670.23%-53.94M | 1,846.98%29.49M | -427.55%-14.25M | -8,042.53%-180.52M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 34.33%27.49M | 23.19%25.17M | 607.37%1.1M | 1,150.00%1.2M | -88.24%18K | -94.58%20.47M | 15,236.30%20.43M | -100.74%-217K | -99.95%96K | -99.89%153K |
| Net common stock issuance | --0 | ---- | ---- | ---- | ---- | -91.56%20.06M | ---- | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | 3,462.32%27.61M | 5,557.49%25.29M | 1,293.67%1.1M | 1,150.00%1.2M | -88.24%18K | 420.13%775K | 2,028.57%447K | --79K | -25.00%96K | --153K |
| Net other financing activities | 68.13%-116K | ---- | ---- | ---- | ---- | 89.09%-364K | 56.41%-68K | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 34.33%27.49M | 23.19%25.17M | 607.37%1.1M | 1,150.00%1.2M | -88.24%18K | -94.58%20.47M | 15,236.30%20.43M | -100.74%-217K | -99.95%96K | -99.89%153K |
| Net cash flow | ||||||||||
| Beginning cash position | -82.87%60.19M | -45.96%63.58M | -52.70%51.55M | -60.23%57.13M | -82.87%60.19M | 719.84%351.41M | -68.09%117.66M | -69.62%108.98M | -15.31%143.64M | 719.84%351.41M |
| Current changes in cash | 124.89%72.49M | 220.25%69.1M | 38.64%12.02M | 83.92%-5.57M | 98.53%-3.06M | -194.38%-291.22M | -231.14%-57.47M | -13.05%8.67M | -118.32%-34.65M | -263.94%-207.77M |
| End cash Position | 120.44%132.68M | 120.44%132.68M | -45.96%63.58M | -52.70%51.55M | -60.23%57.13M | -82.87%60.19M | -82.87%60.19M | -68.09%117.66M | -69.62%108.98M | -15.31%143.64M |
| Free cash flow | 40.36%-62.84M | 189.48%27.95M | -19.84%-26.37M | -38.09%-31.84M | -12.02%-32.59M | -52.51%-105.38M | -81.25%-31.23M | -12.54%-22M | -41.58%-23.05M | -81.46%-29.09M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg